Wang Yang, Lai Junyu, Chen Zhengtao, Sun Liqiang, Ma Yirong, Wu Jianguang
Department of Postgraduate, Jiangxi University of Chinese Medicine, Nanchang, China.
Department of Cardiovascular, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Front Pharmacol. 2024 Nov 5;15:1475975. doi: 10.3389/fphar.2024.1475975. eCollection 2024.
Heart failure (HF) is a clinical condition caused by abnormalities in the heart's structure or function, primarily manifested as diminished ability of the heart to pump blood, which leads to compensatory activation of neurohormones and increased left ventricular filling pressure. HF is one of the fastest-growing cardiovascular diseases globally in terms of incidence and mortality, negatively impacting patients' quality of life and imposing significant medical and economic burdens. Despite advancements in the treatment of HF, hospitalization and mortality remain rates high. In China, Chinese herbal medicine (CHM) has historically played a prominent role in addressing HF, with significant proven efficacy. MicroRNA (miRNA) exerts a pivotal regulatory influence on the maintenance of regular cardiac activity and the progression of HF. MiRNAs, a category of single-stranded RNA molecules, are characterized by their inability to code for proteins. They regulate gene expression by binding to the 3'-untranslated region (3'-UTR) of target mRNAs, thereby influencing the onset and progression of various diseases. Abnormal expression of specific miRNAs is closely associated with HF pathological processes, such as cardiomyocyte apoptosis, myocardial fibrosis, and cardiac hypertrophy. This abnormal expression can influence the pathological progression of HF through the regulation of miRNA expression. This article reviews the regulatory role of miRNAs in HF pathology discusses how CHM compounds and their active ingredients can ameliorate HF pathology through the regulation of miRNA expression. In conclusion, miRNAs represent promising therapeutic targets for HF, and CHM provides a novel strategy for treatment through the regulation of miRNA expression. Future studies must delve deeper into the precise mechanisms by which CHM modulates miRNAs and fully explore its potential for clinical application in HF treatment.
心力衰竭(HF)是一种由心脏结构或功能异常引起的临床病症,主要表现为心脏泵血能力下降,进而导致神经激素的代偿性激活和左心室充盈压升高。就发病率和死亡率而言,HF是全球增长最快的心血管疾病之一,对患者的生活质量产生负面影响,并带来巨大的医疗和经济负担。尽管HF治疗取得了进展,但住院率和死亡率仍然很高。在中国,中药在治疗HF方面一直发挥着重要作用,已证实具有显著疗效。微小RNA(miRNA)对维持正常心脏活动和HF进展发挥着关键的调节作用。miRNA是一类单链RNA分子,其特点是不能编码蛋白质。它们通过与靶mRNA的3'非翻译区(3'-UTR)结合来调节基因表达,从而影响各种疾病的发生和发展。特定miRNA的异常表达与HF病理过程密切相关,如心肌细胞凋亡、心肌纤维化和心脏肥大。这种异常表达可通过调节miRNA表达影响HF的病理进展。本文综述了miRNA在HF病理中的调节作用,讨论了中药化合物及其活性成分如何通过调节miRNA表达改善HF病理。总之,miRNA是HF有前景的治疗靶点,中药通过调节miRNA表达提供了一种新的治疗策略。未来的研究必须更深入地探究中药调节miRNA的精确机制,并充分探索其在HF治疗中的临床应用潜力。